Immunotherapy before surgery shows promise for early lung cancer
NCT ID NCT02818920
First seen Mar 23, 2026 · Last updated Apr 29, 2026 · Updated 7 times
Summary
This study tested giving the immunotherapy drug pembrolizumab before and after surgery for people with early-stage non-small cell lung cancer. The goal was to see if this approach is safe and does not delay surgery. 35 participants were enrolled. The study looked at how the drug affects immune cells in the tumor. While pembrolizumab is already approved for advanced lung cancer, its use in this earlier setting was experimental.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
Conditions
Explore the condition pages connected to this study.